🔗 Share this article

Given that the United States proceeds with historic adjustments to its vaccine guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on Covid vaccines during the pandemic and has zeroed in on potential deaths following Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Health officials had intended to reveal sweeping revisions to the childhood vaccine schedule in December, synchronizing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US at odds with a large portion of the world with little proof for public health gain. The planned update has been delayed until the next year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the office this year.

A New Direction at the Agency

Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Høeg and Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for ending certain childhood shot schedules in the US in order to be more similar to Denmark's approach, a society with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Qualifications

The appointee has no obvious experience in pharmaceutical research, oversight or administrative roles, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the CDER, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a sizeable institution. She lacks background in drug approvals.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who ran CBER have had.”

The drug center has an enormous workload at the agency, she emphasized.

“The public just focuses on the new drug program, but the off-patent medication office authorizes thousands of generic drugs. There’s a biosimilars division, OTC medication office and more, and each of these need to be looked after,” Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the job, which manages over 5,000 personnel. “It’s a huge administrative position, if you do it right,” she concluded.

Agency Reaction and Contentious Initiatives

Regarding questions about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among agency officials on vaccines, a spokesperson stated that the “concerns rely on incorrect assumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson explained, citing the period Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a controversial expedited medication authorization process that reportedly troubled her preceding directors. “By what process are these therapies being selected for this fast-track system? Who makes the calls?” Dr. Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the FDA seems to be moving towards laxer rules of most medications, with the exception of shots.”

Public History on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, track record, critics said. She released a research paper using unconfirmed volunteer-provided data to assess the rate of myocarditis after Covid immunization. She advised the Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Included in her “policy goals” for the current federal leadership featured altering regulations for recently developed shots and ending “non-essential” vaccines, she said after the election on a podcast. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from getting Covid vaccines.

“She is an all-around true believer who commences with her conclusions and tailors the evidence to retrofit the evidence in a extremely disingenuous, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|